← Back to Search

Multidisciplinary Health Intervention for Blood Cancer

N/A
Waitlist Available
Led By Andrew S Artz
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hematologic malignancy or disease as indication for HCT
>= 65 years at time of planned HCT infusion
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is studying a multidisciplinary intervention to help older adults with blood cancers who are planning a stem cell transplant. The intervention includes multiple healthcare professionals and is aimed at improving fitness and the ability to bounce back after transplant.

Who is the study for?
This trial is for older adults (65+) with blood cancers who are candidates for stem cell transplantation. Participants must be able to read English, Spanish, or Mandarin and consent to the study's requirements. Those with prior allogeneic transplants or conditions that make study procedures unsafe are excluded.Check my eligibility
What is being tested?
The trial is testing a multidisciplinary approach involving various healthcare professionals aimed at improving fitness and recovery post-transplant in older adults. It includes health promotion activities, quality-of-life assessments, and questionnaires.See study design
What are the potential side effects?
Since this trial focuses on non-medical interventions like health promotion and questionnaires rather than drugs or medical treatments, traditional side effects are not applicable. However, participants may experience fatigue or stress related to additional appointments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I need a stem cell transplant for my blood cancer.
Select...
I am 65 years or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of multidisciplinary team (MDT) (met 90 percent threshould, yes / no)
Secondary outcome measures
Dose intensity of resiliency bolstering
Functional independent survival (FIS)
Library of MDT-facilitated intervention
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive care (MDT-intervention)Experimental Treatment3 Interventions
Patients participate in the MDT-intervention including access to a HCT physician, a geriatrician, physical or occupational therapist, dietician, and a social worker for three months before HCT and up to 100 days after HCT.

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
570 Previous Clinical Trials
1,922,500 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,718 Previous Clinical Trials
40,963,351 Total Patients Enrolled
1 Trials studying Blood Cancers
70 Patients Enrolled for Blood Cancers
Andrew S ArtzPrincipal InvestigatorCity of Hope Comprehensive Cancer Center
1 Previous Clinical Trials
164 Total Patients Enrolled

Media Library

Multidisciplinary Intervention Clinical Trial Eligibility Overview. Trial Name: NCT04914338 — N/A
Blood Cancers Research Study Groups: Supportive care (MDT-intervention)
Blood Cancers Clinical Trial 2023: Multidisciplinary Intervention Highlights & Side Effects. Trial Name: NCT04914338 — N/A
Multidisciplinary Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04914338 — N/A
~6 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top